Načítá se...
Mortality Benefit of Alirocumab: A Bayesian Perspective
BACKGROUND: The ODYSSEY OUTCOMES (Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome) trial demonstrated that alirocumab reduced major cardiovascular events. However, because of the hierarchical testing strategy used for the multiple outcomes examined, the observed reduction in all...
Uloženo v:
| Vydáno v: | J Am Heart Assoc |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6818032/ https://ncbi.nlm.nih.gov/pubmed/31599200 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.119.013170 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|